Genocea Biosciences Inc (GNCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
56
About the Report
About the Report
Summary
Genocea Biosciences Inc (Genocea), formerly GenoceaInc, is a cancer vaccines provider. The company discovers and develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. It provides Gen-009 and Gen-010 neoantigen cancer Vaccine pipeline.Genoceaatlas technology uses a cellular assay to comprehensively re-create a patient's actual immune response to cancer. The company's Gen-009 cancer vaccines are being designed to educate T cells to recognize and attack specific targets and thereby kill cancers. It offers pre-clinical and clinical investigational immunotherapies. The compnay's partnership program includes antigen discovery, immune responsw profiling, Gen-003 for general herpes and other disease programs.Genocea is headquartered in Cambridge, Massachusetts, the US.
Genocea Biosciences Inc (GNCA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Genocea Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genocea Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Genocea Biosciences Secures USD16.09 Million in Venture Funding from Auriga Partners 12
Genocea Biosciences Raises USD 0.4 Million In Venture Financing 13
Genocea Biosciences Raises USD 30 Million In Series C Financing 14
Partnerships 16
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 16
Genocea Biosciences Enters into Agreement with US Oncology Research 17
Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 18
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 19
Licensing Agreements 20
Genocea Biosciences Enters into Licensing Agreement with Oncovir 20
Equity Offering 21
Genocea Biosciences to Raise up to USD23.3 Million in Public Offering of Shares 21
Genocea Biosciences Raises USD53.4 Million in Public Offering of Shares 22
Genocea Biosciences Raises USD1.6 Million in Public Offering of Preferred Shares 24
Genocea Biosciences Raises USD50 Million in Public Offering of Shares 26
Genocea Biosciences Raises USD52 Million in Public Offering of Shares 28
Genocea Biosciences Raises USD2 Million in Private Placement of Shares 30
Genocea Biosciences Withdraws Public Offering of Shares 32
Genocea Biosciences Completes IPO For USD 66 Million 33
Genocea Biosciences Inc-Key Competitors 35
Genocea Biosciences Inc-Key Employees 36
Genocea Biosciences Inc-Locations And Subsidiaries 37
Head Office 37
Recent Developments 38
Financial Announcements 38
Aug 02, 2018: Genocea reports second quarter 2018 financial and operating results 38
May 10, 2018: Genocea Reports First Quarter 2018 Financial and Operating Results 39
Feb 15, 2018: Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results 40
Nov 02, 2017: Genocea Reports Third Quarter 2017 Financial Results 42
Aug 09, 2017: Genocea Biosciences Reports Second Quarter 2017 Financial Results 44
May 04, 2017: Genocea Reports First Quarter 2017 Financial Results 45
May 04, 2017: Genocea Biosciences Q1 net loss increases 46
Feb 16, 2017: Genocea Reports Fourth Quarter and Year-End 2016 Financial Results 47
Corporate Communications 49
Mar 12, 2018: Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing 49
Feb 12, 2018: Genocea Biosciences Names Ali Behbahani, M.D., As Board Director 50
Mar 06, 2017: Howard Mayer, M.D., of Shire, Joins Genocea Biosciences' Board of Directors 51
Product News 52
09/25/2017: Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccine GEN-009 52
04/18/2018: Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods 53
04/09/2018: Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines 54
Product Approvals 55
Apr 30, 2018: Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
List of Figure
List of Figures
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genocea Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genocea Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Genocea Biosciences Secures USD16.09 Million in Venture Funding from Auriga Partners 12
Genocea Biosciences Raises USD 0.4 Million In Venture Financing 13
Genocea Biosciences Raises USD 30 Million In Series C Financing 14
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 16
Genocea Biosciences Enters into Agreement with US Oncology Research 17
Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 18
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 19
Genocea Biosciences Enters into Licensing Agreement with Oncovir 20
Genocea Biosciences to Raise up to USD23.3 Million in Public Offering of Shares 21
Genocea Biosciences Raises USD53.4 Million in Public Offering of Shares 22
Genocea Biosciences Raises USD1.6 Million in Public Offering of Preferred Shares 24
Genocea Biosciences Raises USD50 Million in Public Offering of Shares 26
Genocea Biosciences Raises USD52 Million in Public Offering of Shares 28
Genocea Biosciences Raises USD2 Million in Private Placement of Shares 30
Genocea Biosciences Withdraws Public Offering of Shares 32
Genocea Biosciences Completes IPO For USD 66 Million 33
Genocea Biosciences Inc, Key Competitors 35
Genocea Biosciences Inc, Key Employees 36
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.